Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Income from Continuing Operations (2022 - 2025)

Historic Income from Continuing Operations for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$54.9 million.

  • Centessa Pharmaceuticals' Income from Continuing Operations fell 2895.5% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 5049.64%. This contributed to the annual value of -$235.8 million for FY2024, which is 5604.26% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Income from Continuing Operations stood at -$54.9 million for Q3 2025, which was down 2895.5% from -$50.3 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Income from Continuing Operations ranged from a high of -$24.9 million in Q2 2023 and a low of -$111.3 million during Q4 2024
  • In the last 4 years, Centessa Pharmaceuticals' Income from Continuing Operations had a median value of -$43.8 million in 2024 and averaged -$49.0 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Income from Continuing Operations surged by 6151.31% in 2023, and later tumbled by 20222.06% in 2024.
  • Over the past 4 years, Centessa Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$43.2 million in 2022, then increased by 14.68% to -$36.8 million in 2023, then tumbled by 202.22% to -$111.3 million in 2024, then skyrocketed by 50.69% to -$54.9 million in 2025.
  • Its last three reported values are -$54.9 million in Q3 2025, -$50.3 million for Q2 2025, and -$26.1 million during Q1 2025.